Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms beta-NF-ATRA, β-NF-ATRA |
Target |
Action degraders |
Mechanism CRABP1 degraders(cellular retinoic acid binding protein 1 degraders), CRABP2 degraders(cellular retinoic acid binding protein 2 degraders) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC48H54N2O9 |
InChIKeyMGBFQQQDJPJUNW-DZHZFLTJSA-N |
CAS Registry2416251-59-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | Japan | 03 Oct 2019 |